The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke

Richard Bulbulia and Alison Halliday
The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke

Richard Bulbulia¹ and Alison Halliday²*

¹Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
²Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

*Corresponding author

Declared competing interests of authors: none

Published October 2017
DOI: 10.3310/hta21570

This report should be referenced as follows:


Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.
Health Technology Assessment

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 06/301/233. The contractual start date was in April 2007. The draft report began editorial review in September 2016 and was accepted for publication in July 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bulbulia et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Editor-in-Chief**

**Professor Hywel Williams**  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

**NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:**  journals.library@nihr.ac.uk
Abstract

The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke

Richard Bulbulia¹ and Alison Halliday²*

¹Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
²Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

*Corresponding author alison.halliday@nds.ox.ac.uk

Background: A successful open surgical operation to remove atheromatous carotid artery narrowing that has not yet caused a stroke (asymptomatic carotid stenosis) carries some procedural risk but, if completed successfully, halves patients’ future annual stroke risk for at least 10 years. A newer, less invasive alternative is carotid stenting, which also carries some procedural risk, especially if the carotid lesion has recently given rise to a stroke (symptomatic carotid stenosis). For both surgery and stenting, improvements in technique (and in medication) have reduced risk. Early studies showed that treating carotid narrowing by stenting, particularly for symptomatic lesions, caused more procedural minor strokes than surgery, but more recent trials in symptomatic and in asymptomatic patients found that both procedures might now be equally safe and effective. However, low patient numbers, short follow-up of the long-term effects on stroke rates and wide confidence intervals mean that worldwide uncertainty persists between carotid surgery and carotid stenting, and national and international guidelines remain unclear as to which is generally better.

Objectives: The second Asymptomatic Carotid Surgery Trial (ACST-2) compares carotid endarterectomy (CEA) with carotid artery stenting (CAS) directly, randomising patients with asymptomatic carotid stenosis for whom a carotid procedure is considered definitely necessary; both procedures seem anatomically feasible, and there is substantial uncertainty as to which of the two would be better for such individuals. Although it will compare procedural risks, the trial’s primary aim is to compare the long-term durability of protection against strokes occurring in the years post procedure due to any remaining or recurrent carotid disease.

Design: Randomised controlled trial comparing CEA with CAS.

Setting: Hospitals in the UK and worldwide, in which carotid procedures are common.

Participants: Men and women with severely stenotic atherosclerotic carotid artery disease, with or without previous stroke but with no recent symptoms from the randomised artery.

Interventions: CEA and CAS.

Outcomes: (1) Periprocedural risk defined as myocardial infarction, stroke or death within 30 days after the randomised procedure and (2) long-term rates of disabling or fatal stroke during follow-up of patients.
Measurement of costs and outcomes: Measurement of intervention costs and stroke costs (periprocedural and during follow-up) and of quality of life [EuroQol-5 Dimensions (EQ-5D®)] for patients in the top six recruiting countries (UK, Italy, Belgium, Germany, Serbia and Sweden), who currently constitute 85% of those randomised.

Progress so far: By the end of March 2016, ACST-2 had included 2125 patients, nearly two-thirds of the planned recruitment of 3600; 1061 were randomly allocated to CEA and 1064 to CAS.

Conclusions: Further funding has been secured and recruitment continues, with completion anticipated by the end of 2019. ACST-2 will report initial results in 2021.

Trial registration: Current Controlled Trials ISRCTN21144362.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 21, No. 57. See the NIHR Journals Library website for further project information. Funding was also received from BUPA Foundation [BUPAF/33(a)/05].
Contents

List of tables ix
List of figures xi
List of abbreviations xiii
Plain English summary xv
Scientific summary xvii

Chapter 1 Rationale and study design 1
Inclusion criteria 1
Exclusion criteria 1

Chapter 2 Recruitment 3

Chapter 3 Data collection 5
Major events 5

Chapter 4 Patient and public involvement 7

Chapter 5 Economic evaluation and quality of life 9

Chapter 6 Interim blinded results 11

Chapter 7 Statistical analysis 15

Chapter 8 Discussion 17
Large-scale randomised evidence comparing the long-term durability of carotid surgery with carotid stenting is needed to avoid moderate biases and random errors 18
Regulatory challenges in conducting an international trial 19
A change in clinical practice favouring treatment of asymptomatic carotid patients with medical therapy alone 19
Concerns about the short-term safety of carotid stenting 20
Meta-analysis plans 20
Over 5000 patients randomised to carotid endarterectomy versus carotid artery stenting can detect plausible differences in outcomes between carotid endarterectomy and carotid artery stenting, and ACST-2 will provide most of these patients 20
Recruitment strategy developed to reach target of 3600 by end 2019 20
Cost analysis 21
Streamlined trial design necessary to provide reliable evidence at reasonable cost 21

Chapter 9 Conclusion 23

Acknowledgements 25

References 27
<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix 1</td>
<td>Trial flow diagram</td>
<td>29</td>
</tr>
<tr>
<td>Appendix 2</td>
<td>Hub-and-spoke model for ACST-2 in North East England</td>
<td>31</td>
</tr>
<tr>
<td>Appendix 3</td>
<td>Italian collaborators’ newsletter</td>
<td>33</td>
</tr>
<tr>
<td>Appendix 4</td>
<td>Randomisation</td>
<td>35</td>
</tr>
<tr>
<td>Appendix 5</td>
<td>One-month form</td>
<td>37</td>
</tr>
<tr>
<td>Appendix 6</td>
<td>One-year form</td>
<td>39</td>
</tr>
</tbody>
</table>
List of tables

TABLE 1 Baseline characteristics of ACST-2 participants 11

TABLE 2 Use of triple therapies at 1 month: 1921 patients with an entered and verified 1-month follow-up form 12

TABLE 3 Triple therapies recorded on the 2015 annual follow-up form: 1363 patients with an entered and verified annual follow-up form 12

TABLE 4 Compliance with allocated treatment 13

TABLE 5 Cerebral protection devices used in stenting: 887 patients who received CAS with an entered and verified 1-month follow-up form 13

TABLE 6 Comparison of the contemporary US carotid trial vs. ACST-1 and ACST-2 costs 22
List of figures

FIGURE a  ACST-1, a comparison of immediate vs. deferred CEA: the 10-year stroke risk in patients with tight asymptomatic carotid stenosis who are already on triple medical therapy (statin, antithrombotic and antihypertensive)  xviii

FIGURE 1  Recruitment per country (to the end of December 2015)  3

FIGURE 2  Total recruitment by month (March 2010 to December 2015)  4
## List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACST-1</td>
<td>The first Asymptomatic Carotid Surgery Trial</td>
</tr>
<tr>
<td>ACST-2</td>
<td>The second Asymptomatic Carotid Surgery Trial</td>
</tr>
<tr>
<td>CABG</td>
<td>coronary artery bypass grafting</td>
</tr>
<tr>
<td>CAS</td>
<td>carotid artery stenting</td>
</tr>
<tr>
<td>CEA</td>
<td>carotid endarterectomy</td>
</tr>
<tr>
<td>CSTC</td>
<td>Carotid Stenosis Triallists’ Collaboration</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTSU</td>
<td>Clinical Trial Service Unit</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>EuroQol-5 Dimensions</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>ICSS</td>
<td>International Carotid Stenting Study</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NIHR</td>
<td>National Institute for Health Research</td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
</tr>
</tbody>
</table>
Plain English summary

Stroke is a leading cause of death and disability worldwide. Narrowing in the carotid arteries (the main arteries in the neck that supply blood to the brain), caused by a build-up of fatty deposits, is responsible for around 20% of all strokes. People with this narrowing may be asymptomatic, that is, they may have no symptoms until fragments of the fatty deposits fall off, lodge in the brain and cause a stroke. The standard procedure to prevent this, carotid endarterectomy (CEA), involves operating on the neck to remove the fatty deposits from the artery before they cause stroke-like symptoms or a major stroke. This surgery involves some immediate risk but, if successful, provides long-term protection against the narrowing that causes a stroke. An alternative procedure is carotid artery stenting (CAS), which involves placing a fine wire mesh tube (called a stent) inside the narrowed artery to hold it open. Stenting avoids neck surgery, but we do not yet know how it compares with surgery in terms of the immediate risks or long-term benefits, as previous studies comparing these procedures in asymptomatic patients were too small.

The second Asymptomatic Carotid Surgery Trial (ACST-2) will compare the short-term risks and long-term benefits of carotid surgery with carotid stenting in 3600 patients with asymptomatic carotid artery lesions. By the end of March 2016, ACST-2 had included 2125 patients, nearly two-thirds of the planned recruitment of 3600. A total of 1061 patients were randomly allocated to CEA and 1064 were randomly allocated to CAS. Further funding has been secured and recruitment continues, with completion anticipated by the end of 2019. The ACST-2 will report initial results in 2021 with two main aims: first, to compare the small (about 1%), but important, early risk of fatal or disabling stroke damage from the procedure itself (within 30 days of the intervention) and, second, to compare the long-term annual stroke risks after CEA and CAS.
Scientific summary

Background

The second Asymptomatic Carotid Surgery Trial (ACST-2) is a randomised controlled trial (RCT) of 3600 patients with tight asymptomatic carotid artery stenosis comparing intervention with carotid endarterectomy (CEA) with carotid stenting (CAS). Patients will be followed up long term (median follow-up of around 10 years) to determine both the short-term hazards of intervention and, more importantly, the long-term durability of protection against stroke.

Atheromatous carotid artery lesions can partially block one or both of the arteries in the neck that supply the brain. Such lesions can rupture suddenly, causing a major or minor stroke. Significant (e.g. 70–90%) carotid artery narrowing that has not yet caused a stroke (asymptomatic stenosis) is an increasingly common incidental finding due to widespread use of vascular imaging for investigating stroke and stroke-like symptoms. Imaging methods include ultrasound, computed tomography or magnetic resonance imaging, and these scans can reveal severe stenoses that indicate an increased future risk of stroke.

In patients with tight carotid stenosis, long-term triple therapy (lipid-lowering, antihypertensive and antithrombotic treatment) lowers the risk of stroke and is widely used. However, when future risk of stroke from carotid stenosis remains, this can be reduced further by surgery (CEA) or stenting (CAS) in patients with an otherwise reasonable life expectancy. The first Asymptomatic Carotid Surgery Trial (ACST-1) (in 3000 asymptomatic patients) compared CEA with no carotid procedure and showed that, even in patients on triple therapy, CEA substantially reduced patients’ 10-year stroke risk (Figure a).

Our current trial, ACST-2, is an international RCT comparing CEA with CAS in patients thought likely to benefit from preventative carotid intervention. Symptomatic carotid artery lesions are those that have already caused a stroke; they are more dangerous to touch (i.e. associated with a high procedural stroke risk) and are not the subject of this study. Asymptomatic lesions that have not recently caused stroke can, however, be treated fairly safely by CEA or by CAS, thus providing long-term protection against stroke. There may be substantial uncertainty, shared by the doctor and the patient, about whether or not CEA or CAS is the preferred treatment and, in such circumstances, randomisation via ACST-2 is appropriate.

Objectives and outcome measures

The primary objectives of the trial are to compare periprocedural risks, defined as myocardial infarction, stroke and death within 30 days of undertaking the randomised procedure (CEA or CAS), and to follow up patients in the longer term (median follow-up about 10 years) to obtain the rates of disabling or fatal stroke in this cohort during the years after CEA or CAS.

The secondary objectives include comparing health-related quality of life, which is to be assessed as part of our health economic evaluation. Depending on the numbers of participants who are eventually randomised, ACST-2 (and associated individual patient data meta-analyses) may help identify subgroups of patients in whom one of the procedures is clearly preferable.

Trial registration

This trial is registered as ISRCTN21144362.
Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research. Funding was also received from BUPA Foundation [BUPAF/33(a)/05].

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research. Funding was also received from BUPA Foundation [BUPAF/33(a)/05].

**FIGURE a** ACST-1, a comparison of immediate vs. deferred CEA: the 10-year stroke risk in patients with tight asymptomatic carotid stenosis who are already on triple medical therapy (statin, antithrombotic and antihypertensive). (a) Any stroke (or perioperative death); and (b) non-perioperative stroke. SE, standard error.
Chapter 1 Rationale and study design

The second Asymptomatic Carotid Surgery Trial (ACST-2) is a pragmatic international multicentre randomised controlled trial (RCT) that directly compares carotid surgery with carotid artery stenting (CAS). It includes patients thought to definitely need an intervention for asymptomatic carotid stenosis, but in whom there is substantial uncertainty as to whether or not to opt for carotid endarterectomy (CEA) or CAS. The ACST-2 seeks to randomise such individuals to either CEA or CAS to compare both the immediate hazards of the two procedures when carried out by experienced doctors with an approved track record and the long-term durability of protection against stroke conferred by both procedures. The trial will also collect the stroke rates in the patients over 5–10 years of follow-up, with follow-ups planned until 2025. The trial seeks to recruit any patient with a carotid lesion that has not recently (i.e. within 6 months) caused any symptoms (i.e. an asymptomatic lesion), who would be expected to benefit from a carotid procedure to reduce the risk of future stroke, and in whom there is clinical uncertainty as to which is the preferred treatment.

Potentially eligible trial participants should already be on suitable drug therapy for stroke prevention and be likely to live for at least 5 years, giving them long enough to benefit from a stroke prevention procedure (CEA or CAS). Prior to trial entry, non-invasive arch angiography [computed tomography (CT) or magnetic resonance imaging (MRI)] is also undertaken to ensure suitability for both procedures. These tests are routinely carried out before CAS and commonly, but not invariably, prior to CEA.

Randomisation of patients is by 1 : 1 allocation to CEA or CAS using a minimisation algorithm to ensure that both groups are well matched for key baseline prognostic factors that may determine early and long-term stroke risk. After intervention, patients are neurologically reassessed, including duplex scanning, and their drug treatment is adjusted if necessary before discharge. Early patient experience with both treatments is similar apart from the discomfort and wound care that is associated with open surgery, and the use of general versus local anaesthetic, which is determined by the centre’s standard of care (see Appendix 1).

Inclusion criteria

Patients being considered for ACST-2 should have:

- carotid artery stenosis detectable by duplex ultrasonography, with no ipsilateral carotid territory symptoms and no previous procedures carried out on it
- already started any appropriate medical treatment (e.g. statin, antithrombotic and antihypertensive therapy) and already recovered from any necessary coronary procedures [e.g. coronary artery bypass grafting (CABG)]
- been assessed to be fit and willing for follow-up in person at 1 month post intervention and subsequently by annual letter
- investigations that show that both procedures (CEA and CAS) appear to be practical and appropriate
- no definite preference or clinical indication about whether to treat the carotid narrowing with CEA or CAS and their doctor should see no clear indication/contraindication for either procedure.

Exclusion criteria

Patients would be excluded from ACST-2 if they had:

- a small likelihood of worthwhile benefit (e.g. very low risk of stroke because stenosis is very minor) or major comorbidity or life-threatening disease, such as advanced cancer
- an assessment showing that they were unsuitable for one of the procedures
- been found to be unfit for major surgery.
Chapter 2 Recruitment

An international collaborative network has been established and comprises doctors across 27 countries. The network has been investigated and approved by our Technical Management Committee and by their local ethics and research committees. By March 2016, 2125 patients had been recruited from 110 centres worldwide. Recruitment pathways in the trial are similar to those used in routine clinical practice.

The ACST-2 has been designed to minimise the burden of research on the collaborators. The initial patient assessment determines that they are on suitable drug therapy for stroke prevention and that the patient is likely to live for at least 5 years, giving them long enough to benefit from a stroke prevention procedure (CEA or CAS). Prior to trial entry, non-invasive MRI or CT arch angiography is undertaken to ensure suitability for both procedures; this is usually done before CAS and commonly, but not invariably, done prior to CEA, and hence can be readily integrated into the participant’s care pathway.

The usual CAS procedure involves passing a guide wire from the femoral artery up to the aortic arch to gain access to the carotid artery. In some cases the anatomy of the aortic arch can be sufficiently tortuous to make CAS more difficult or hazardous; pre-randomisation aortic arch imaging with MRI or CT ensures that CAS is likely to be technically feasible. In routine practice, a duplex Doppler scan is often performed 1 month after the procedure to check the artery is open. Therefore, such a scan is used in this trial to check patency of the carotid artery 1 month after intervention, thereby confirming technical success. At least one clinical follow-up in outpatients is routine care for all carotid interventions and this is usually done 1 month after the procedure in this trial.

Within the UK we used a novel hub-and-spoke recruitment model, which allowed centres (i.e. the ‘spoke’) that offered one, but not both, treatments (usually CEA but not CAS) to identify patients who were eligible to enter the trial. The patients were then assessed (including use of MRI or CT) and then, after randomisation and depending on the treatment allocated, treated locally using CEA or sent for CAS to the ‘hub’ hospital (see Appendix 2).

One-third of European carotid procedures are performed in Italy, one-third are performed in Germany and the remaining one-third are performed in other European countries. Although Italy is the top recruiting country in the ACST-2, the UK is the second highest recruiter, accounting for about 20% of randomised patients (Figures 1 and 2).

![Figure 1](image-url)
FIGURE 2 Total recruitment by month (March 2010 to December 2015). Number of centres that ever recruited a patient and cumulative recruitment.
Chapter 3 Data collection

Randomisation is carried out by a telephone randomisation service (24-hour freephone number) or via a password-protected website via the internet. The collaborator is informed of the allocated treatment and the participant is ascribed a unique patient identifier number. The collaborator then either faxes or posts the randomisation form and the signed consent form to the ACST-2 trial office, which is based in the Nuffield Department of Surgical Science, University of Oxford, Oxford, UK. Procedural and post-procedure data are subsequently collected on a 1-month follow-up form completed by the collaborator and returned to the ACST-2 trial office. Data from these forms are entered on a trial database, which is held on secure servers on behalf of ACST-2 at the Clinical Trials Service Unit, University of Oxford, Oxford, UK [that have worked with us in designing and carrying out much of the work in the first Asymptomatic Carotid Surgery Trial (ACST-1) and ACST-2].

Annual follow-up of the patients in the trial is co-ordinated by the central ACST-2 office and annual questionnaires are sent either directly to the patient or to the collaborator, depending on local agreements.

Major events

These are classified as:

- strokes within the first post-procedural month or during the long-term follow-up
- peri- or post-procedural myocardial infarction (MI) within the first 30 days
- death.

Information on these events is collected on the 1-month follow-up form or on the annual follow-up form. Further information, if required, is then requested from the collaborator. Once this information has been received by the ACST-2 office, a summary of the anonymised information is passed for adjudication. The Endpoint Review Committee reviews all such events and classifies the nature and severity of any of the strokes. Information on the types and number of major events is reviewed by the independent Data Monitoring Committee.
Chapter 4 Patient and public involvement

The aims and design of ACST-2 have been discussed with the Oxford Clinical Trial Service Unit (CTSU) patient focus group, which was established in 2012 to allow members of the public who have, or are at risk of, vascular disease to criticise and help evaluate ongoing and planned studies conducted by the CTSU.

Mr David Simpson is the lay member on the ACST-2 Trial Steering Committee. He was closely involved in study design, drafting the trial protocol and original patient information leaflet, and eloquently represents the public interest, both formally at annual Trial Steering Committee meetings and informally throughout the years. His role is ongoing as the trial continues.

The ACST-2 trial was adopted by the Stroke Research Network as soon as funding was confirmed by Health Technology Assessment (HTA) programme. This helped us with local contacts, meetings, ethics approval applications, recruitment (of the planned 20% of UK patients) and follow-up in the UK. Annual Stroke Network meetings in Newcastle and London were particularly helpful by enabling us to give platform presentations of our work and discuss it with attendees from potential new centres in front of our posters. We also attended, presented and had stands at the Thames Cardiovascular Network Group meetings in 2013 and 2014, the Vascular Society (the UK National Society for Vascular Surgery) and the British Society of Interventional Radiology (for UK interventional radiologists). The annual UK Stroke Forum was also important; attendees came from every stroke care discipline and included stroke sufferers and representatives from patient groups. We have had a stand at most of these meetings since the trial’s inception, winning a prize for our novel UK hub-and-spoke recruitment model at the UK Stroke Forum.
Chapter 5  Economic evaluation and quality of life

The design of ACST-2 includes a health economic component with evaluation of resource use during treatment and follow-up. The use of UK data will be particularly relevant to the NHS because much of the evidence on costs of CEA and, particularly, CAS has been based on evidence from studies outside the UK. The main components for current and future study will be (1) initial procedural costs, (2) short-term retreatment costs (repeat or further procedures within 1 month), (3) costs of any MIs and strokes within the first month and (4) the costs of any strokes after the first month, almost all of which will not be procedural. Duration of hospital stay is also recorded. At annual follow-ups with the patients, we seek information about strokes or carotid procedures beyond the first month and standard costs will be assumed for these procedures. Economic analyses will evaluate stroke-related quality of life at 1 month after the trial procedures as well as short- and longer-term stroke outcomes and costs.

Annual follow-up questionnaires sent by the trial office to the patient are used to collect data on whether or not the patient has had a subsequent stroke or further treatment on their carotid arteries. In addition, we have extended collection of the standard EuroQol-5 Dimensions (EQ-5D®) from the UK alone to five more countries (Belgium, Germany, Italy, Serbia and Sweden), accounting for 85% of the patients recruited so far. All stroke patients will be and have been asked annually how their stroke still affects them. Their current medication, including names and dosage of all blood pressure, antithrombotic and lipid-lowering drugs prescribed, has been recorded for analysis.
Chapter 6 Interim blinded results

Unblinded results for the trial will be reported after patient recruitment is complete (and, if recruitment continues at the present rate, the target of 3600 participants will be reached by December 2019) and this report is planned for 2021. Long-term follow-up (which is less onerous and usually by direct patient letter with confirmation of any strokes through the participating physician) will continue until December 2025, after which a final publication will report long-term results in late 2026.

Data on the baseline characteristics of participants recruited to date are available (Table 1). Around one-quarter of participants are > 75 years old and around one-third are female. Diabetes mellitus is more common in ACST-2 than in ACST-1 (one-third of ACST-2 participants have diabetes mellitus), and almost half of the participants had prior evidence of stroke (clinically evident stroke or a silent infarction detected on pre-procedural cross-sectional brain imaging), leaving them at higher stroke risk without appropriate carotid intervention. Owing (in part) to the minimisation algorithm used during randomisation, these characteristics are similar in patients randomised to stenting and surgery.

The use of triple medical therapy is excellent at baseline and maintained or improved during long-term follow-up (Tables 2 and 3). Predictably, CAS is associated with a much higher rate of dual antiplatelet therapy at 1 month post procedure than with CEA, but this difference largely disappears with longer-term follow-up. Over 50% of patients are receiving either rosuvastatin or atorvastatin, with one-quarter taking simvastatin.

<table>
<thead>
<tr>
<th>TABLE 1 Baseline characteristics of ACST-2 participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristic</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Characteristic, n (%)</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Age (years), n (%)</td>
</tr>
<tr>
<td>&lt; 65</td>
</tr>
<tr>
<td>65–74</td>
</tr>
<tr>
<td>≥ 75</td>
</tr>
<tr>
<td>Median age (years)</td>
</tr>
<tr>
<td>Echolucent, n (%)</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>Contralateral stenosis, n (%)</td>
</tr>
<tr>
<td>&lt; 50</td>
</tr>
<tr>
<td>50–79</td>
</tr>
<tr>
<td>80–99</td>
</tr>
<tr>
<td>100</td>
</tr>
<tr>
<td>Median</td>
</tr>
</tbody>
</table>

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bulbulia et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
### TABLE 1 Baseline characteristics of ACST-2 participants (continued)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Trial group</th>
<th>CEA (N = 1061)</th>
<th>CAS (N = 1064)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipsilateral stenosis, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>14 (1)</td>
<td>15 (1)</td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>6 (1)</td>
<td>8 (1)</td>
<td></td>
</tr>
<tr>
<td>60–69</td>
<td>29 (3)</td>
<td>29 (3)</td>
<td></td>
</tr>
<tr>
<td>70–79</td>
<td>346 (33)</td>
<td>344 (32)</td>
<td></td>
</tr>
<tr>
<td>80–99</td>
<td>666 (63)</td>
<td>667 (63)</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>80</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg), n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 140</td>
<td>653 (62)</td>
<td>643 (60)</td>
<td></td>
</tr>
<tr>
<td>141–160</td>
<td>311 (29)</td>
<td>328 (31)</td>
<td></td>
</tr>
<tr>
<td>161–180</td>
<td>80 (8)</td>
<td>72 (7)</td>
<td></td>
</tr>
<tr>
<td>&gt; 180</td>
<td>17 (2)</td>
<td>20 (2)</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 2 Use of triple therapies at 1 month: 1921 patients with an entered and verified 1-month follow-up form

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Allocated to</th>
<th>CAS (N = 932)</th>
<th>CEA (N = 939)</th>
<th>Total (N = 1871)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid lowering, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet or anticoagulant, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On at least one of aspirin or clopidogrel, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both aspirin and clopidogrel, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 3 Triple therapies recorded on the 2015 annual follow-up form: 1363 patients with an entered and verified annual follow-up form

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Allocated to</th>
<th>CAS (N = 676)</th>
<th>CEA (N = 687)</th>
<th>Allocated total (N = 1363)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid lowering, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet or anticoagulant, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On at least one of aspirin or clopidogrel, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both aspirin and clopidogrel, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Compliance: because the trial is ongoing, final compliance is not available. As of March 2016, the overall crossover rate was 3.6% and a further 5.3% of patients were still awaiting intervention, but this number will likely reduce with time (Table 4). The mean time from randomisation to treatment was similar for both CEA (23 days) and CAS (26 days).

Techniques: similar numbers of CEA were performed under general anaesthesia (56%) and local/regional anaesthesia (44%), but the majority of carotid stents were performed under local anaesthetic (94%). Carotid patching was used in 44% of patients undergoing CEA and 22% of CEA patients were shunted. For CAS, eight types of stent were used (46% tapered) and WALLSTENT™ (Boston Scientific Corporation, Marlborough, MA, USA) was the most commonly used device. Cerebral protection devices were used for 86% of CAS (Table 5) and eight types of cerebral protection device were employed (79% filters, 10% proximal systems), including flow reversal and flow arrest systems (see Table 5).

The ACST-2 provides yearly reports to the independent Data Monitoring Committee of confirmed strokes, MI and deaths within 1 month of treatment and of long-term stroke rates. With their consent, in our first 1000 patients we have reported an overall (i.e. blinded) 30-day rate of disabling stroke or death of around 1%, which compares favourably with that seen for CEA alone in ACST-1 (1.7%), confirming that ACST-2 collaborators are performing trial procedures to a high standard.

### TABLE 4 Compliance with allocated treatment

<table>
<thead>
<tr>
<th>Allocated procedure</th>
<th>1-month follow-up form entered and verified</th>
<th>Procedure not yet done</th>
<th>Crossover from allocation</th>
<th>Procedure as allocated</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS</td>
<td>960</td>
<td>61</td>
<td>41</td>
<td>858</td>
</tr>
<tr>
<td>CEA</td>
<td>961</td>
<td>41</td>
<td>29</td>
<td>891</td>
</tr>
<tr>
<td>Total</td>
<td>1921</td>
<td>102</td>
<td>70</td>
<td>1749</td>
</tr>
</tbody>
</table>

### TABLE 5 Cerebral protection devices used in stenting: 887 patients who received CAS with an entered and verified 1-month follow-up form

<table>
<thead>
<tr>
<th>Device type</th>
<th>Device name</th>
<th>Number used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filter</td>
<td>Emboshield (Abbott Vascular, CA, USA)</td>
<td>204</td>
</tr>
<tr>
<td>Filter</td>
<td>FilterWire (Boston Scientific Corp., MA, USA)</td>
<td>171</td>
</tr>
<tr>
<td>Filter</td>
<td>Spider (Medtronic, Minneapolis, MN, USA)</td>
<td>116</td>
</tr>
<tr>
<td>Filter</td>
<td>Accunet (Abbott Vascular, CA, USA)</td>
<td>60</td>
</tr>
<tr>
<td>Filter</td>
<td>AngioGaurd (Cordis, Baar, Switzerland)</td>
<td>44</td>
</tr>
<tr>
<td>Filter</td>
<td>FiberNet (Lumen Biomedical Inc., MN, USA)</td>
<td>1</td>
</tr>
<tr>
<td>Filter</td>
<td>Wirion System (Gardia Medical, Caesarea, Israel)</td>
<td>1</td>
</tr>
<tr>
<td>Proximal occlusion</td>
<td>Mo.Ma (Medtronic, Minneapolis, MN, USA)</td>
<td>131</td>
</tr>
<tr>
<td>Proximal occlusion</td>
<td>Gore Flow Reversal (Gore &amp; Associates, Putzbrunn, Germany)</td>
<td>28</td>
</tr>
<tr>
<td>Distal balloon</td>
<td>Twin One (Minvasys, Paris, France)</td>
<td>3</td>
</tr>
<tr>
<td>Distal balloon</td>
<td>Viatrac (Abbott Vascular, Santa Clara, CA, USA)</td>
<td>1</td>
</tr>
<tr>
<td>None</td>
<td></td>
<td>127 (14%)a</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>887</td>
</tr>
</tbody>
</table>

*a Percentage of cases that did not have a cerebral protection device.*
Chapter 7  Statistical analysis

No material difference in fatal or disabling procedural events is expected (≈1% in each group), so power calculations for this outcome are not given. The primary outcome of particular interest is the stroke risk in the period > 30 days post procedure, but the rates > 5 years post procedure will provide an important subgroup analysis. Accordingly, person-years accrued are more relevant than numbers of patients randomised. For the main outcome of the annual stroke rate after day 30 (i.e. after the end of the perioperative period), ACST-2 will have 18,000 person-years in its first report (2021) and 36,000 by December 2025.

If mature results from ACST-2 show little difference in long-term stroke rates, this key result will be established reliably in the first report and even more reliably by the time of the final report (2026). However, there could be important absolute differences in long-term stroke rates. Suppose, for example, that the stroke rate per decade is 6% after CEA and 9% after CAS, a clinically meaningful difference (with stroke rate ratio = 0.67, easily compatible with the results from the previous trials). Then, with 18,000 person-years by mid-2020, the stroke rate would have about a 70% chance of getting a p-value < 0.05 and a 50% chance of getting a p-value < 0.01. However, with 36,000 person-years (as of December 2025), it would have a 93% chance of getting a p-value < 0.05 and an 82% chance of getting a p-value < 0.01. Moreover, its expected result of 120 versus 180 strokes would ensure high significance (p = 0.002) in a meta-analysis combining it with the apparently null final results from the previous (small) trials.
Chapter 8 Discussion

Almost 200,000 carotid procedures (surgery or stenting) are performed annually, commonly on asymptomatic patients with carotid stenosis, although numbers in the UK are presently lower than in some other European countries. Regardless of how many should be performed here or elsewhere, as long as such procedures continue to be performed widely, large-scale randomised evidence directly comparing surgery with stenting is needed.

Among 1990s-era asymptomatic patients who were on triple-drug therapy (blood pressure-lowering, lipid-lowering and antithrombotic treatment) in the ACST-1 trial of carotid surgery compared with those who were not, there was net benefit from surgery despite the protective effects of the triple therapy. Among new trials, ECST-2 (European Carotid Surgery Trial) and CREST-2 (Carotid Revascularization Endarterectomy versus Stenting Trial) (surgery vs. no surgery in Europe, surgery vs. no surgery in the USA, stenting vs. no stenting in Europe and stenting vs. no stenting in the USA) are currently recruiting to determine whether or not, for the 2010s era triple therapy asymptomatic patients, carotid procedures are still of net benefit. If these trials confirm by the early 2020s that such procedures are of net benefit, then this will greatly increase use in the UK as well as elsewhere (especially as carotid screening is increasing), strengthening the need, both in the UK and elsewhere, for directly randomised evidence to be available from ACST-2 during the 2020s as to which procedure is better.

The procedural hazards are substantially lower for asymptomatic (1.0% disabling stroke or death in the first 1000 patients in ACST-2) than for symptomatic patients. Even 1.0% is a serious risk, but so too is the risk (over the next 5 or more years) of entirely trusting drug therapy and not doing any protective procedure when severe carotid disease is found in a currently asymptomatic patient. Moreover, recent claims that asymptomatic patients with serious carotid disease are at negligibly low risk on triple-drug therapy are methodologically unsound.

The ACST-2 is already the world’s largest trial of CEA versus CAS in asymptomatic patients. It currently randomises 350–400 patients per year, which is the highest recruitment rate of any large trial of carotid interventions.

Many (43%) of the > 2000 patients recruited to date have had previous ipsilateral stroke symptoms or symptoms in another cerebral territory, or have evidence of brain infarction at the time that they enter ACST-2. A recent analysis of our previous ACST-1 trial data has shown that these patients have a 50% higher risk of future stroke than those who have never had neurological symptoms.

The medical treatments that ACST-2 trial patients take will be analysed in much greater detail than in any previous trial of carotid intervention. The findings from ACST-1, SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) and individual patient data meta-analyses from the Cholesterol Treatment Trialists’ Collaborative Group suggest that addition of statins to antiplatelet and antihypertensive medications will lower overall stroke risk by about one-third (in ACST-1 from about 20% to about 14% over 10 years), but that the addition of CEA will reduce stroke risk still further (halving it in the first 5 years and reducing risk from 15% to 8–9% by 10 years).

If CAS, a newer and less invasive treatment, offers stroke protection which is as good as, or better than, CEA, then it is likely to replace invasive surgery for suitable patients in the future. This would lead to a significant change in practice in the UK as, in marked contrast to practice seen in continental Europe and the USA, very few routine CAS procedures are performed in ‘normal risk for surgery’ patients outside trials. With increasing use, costs of stents, filters and wires for CAS are decreasing and, in some higher-volume centres, costs of CEA and CAS are broadly similar. The shorter hospital stay associated with CAS will also be an advantage, saving hospital in-patient costs. In addition, most CAS is carried out under local anaesthetic, in contrast to CEA for which general anaesthesia is currently used for 50% of patients.
If CAS is as effective as CEA, practice could also change for high stroke risk patients prior to coronary bypass grafting. In the past, prophylactic CEA to reduce stroke risk from bypass has been hazardous, particularly when patients have had recent stroke symptoms, or have ongoing coronary symptoms; with CAS, future hazards might be significantly less.

Large-scale randomised evidence comparing the long-term durability of carotid surgery with carotid stenting is needed to avoid moderate biases and random errors

Some treatments are so clearly beneficial [e.g. antibiotics for severe sepsis or protease inhibitors for the treatment of human immunodeficiency virus (HIV) infection] that RCTs are not required to prove their efficacy. However, most currently unevaluated treatments are likely to have, at best, only moderate treatment effects. But such effects may be worthwhile if the condition being treated is both common and also a significant cause of premature death and major morbidity (e.g. heart attacks and strokes).7

In Europe, > 1 million carotid procedures will be performed on asymptomatic patients during the next decade, thereby preventing around 60,000 strokes. Both carotid surgery and carotid stenting are now established procedures that can be performed with low rates of immediate complications in carefully selected patients treated by experienced clinicians.8 However, it is not clear which procedure provides the most durable long-term protection against stroke. Although RCTs can provide some information about the short-term periprocedural hazards following CEA and carotid artery stenting, such events (i.e. strokes, heart attacks and deaths within 30 days of the procedure) will occur so infrequently that even quite a large trial (e.g. 3000–4000 participants) will lack statistical power to detect a plausible difference in treatment arms. Furthermore, trials always recruit patients from the past, but provide information for patients of the future. Hence, it is possible that the interventions performed during the trial will not accurately reflect contemporary clinical practice. This is particularly relevant in trials of carotid artery stenting, which has a significant learning curve9 and is also undergoing major technological innovation (e.g. new stent designs, cerebral protection devices and direct cervical access) all of which aim to reduce periprocedural stroke risk. Accordingly, estimates of contemporary risks associated with CAS and CEA are best assessed in large registries (and ideally those with mandated patient entry and validated outcomes such as the German mandatory national quality assurance registry published by the Federal Agency for Quality Assurance and the Institute for Applied Quality Improvement and Research in Health Care).10 Such registry data may have sufficient demographic or clinical information to identify particular patient populations in whom carotid surgery or stenting is particularly hazardous.

In contrast, RCTs are necessary to compare the long-term durability of carotid surgery with carotid stenting following a successful procedure. Such a comparison cannot be done reliably in a large cohort study because the choice of intervention is likely to have been strongly influenced by specific patient characteristics, which could determine long-term survival and stroke risk (e.g. more frail patients preferentially being offered a minimally invasive stent procedure, while fitter patients are treated surgically). Data from smaller RCTs of largely symptomatic patients suggest that both carotid surgery and stenting offer good long-term protection against stroke11 and almost all patients receive good triple medical therapy following intervention. Consequently, the rate of stroke in these patients is low (around 5–10% per decade). Therefore, to detect a moderate but clinically worthwhile difference in stroke rates between stenting and surgery, large numbers of patients need to be recruited and, importantly, followed up for at least 5 (but preferably 10) years.

At the outset, sample size calculations suggested a trial of around 5000 participants would allow detection of a 60% decrease in the rate of periprocedural MI with stenting versus surgery (e.g. 2% CEA vs. 0.8% CAS) and an increase of around 60% in the 5-year stroke rate (e.g. 3% CEA vs. 5% CAS) at a p-value of 0.001 with 80% statistical power or at 2P of < 0.05 with 95% power. These possible event rates are based on data from other similar trials and are plausible, clinically meaningful and worthwhile. The ACST-1 had recruited > 3000 patients in 10 years and clearly demonstrated benefits of carotid surgery in
asymptomatic patients < 75 years. Following the presentation of these results to the ACST collaborative group, it was agreed that a trial directly comparing carotid surgery with stenting in asymptomatic patients was the next important step in carotid research. The collaborative group’s previous experience in recruiting substantial numbers of patients to ACST-1 (and mindful of the fact that a ‘non-intervention’ arm in this trial was thought to have made recruitment harder) led to the belief that a target of 5000 for a trial comparing two different interventions for asymptomatic carotid disease was achievable. However, recruitment proved challenging, initially due to unanticipated regulatory hurdles and subsequently due to a change in clinical practice in certain countries and a shift in the balance of ‘uncertainty’ in favour of carotid surgery over stenting.

Regulatory challenges in conducting an international trial

The improvements in clinical trial regulation and oversight that have occurred quite recently in the UK (e.g. multicentre ethics committee reviews and research portfolio status allowing rapid local research and development approvals) have made the conduct of trials in the UK a little easier, but these have not been replicated across continental Europe. Furthermore, rigid interpretation of good clinical practice coupled with strict adherence to the European Clinical Trials Directive has become commonplace. Although both framework documents have some merit, they have made research (and particularly resource-limited academic studies) much more difficult to conduct. In contrast to the UK, where there is now a single interpretation of legal, ethical and regulatory requirements which was applied across all study sites, in continental Europe each study site had an Institutional Review Board, or equivalent, who reviewed the trial protocol, consent, patient information leaflet and indemnity arrangements to satisfy compliance with their interpretation of the prevailing regulatory framework (which differed substantially across institutions). Requests were made frequently for protocol amendments, site-specific consent forms and dedicated indemnification arrangements. Although these were always rebutted, this introduced substantial delays in trial set-up at each site and, hence, recruitment was slow to start.

A change in clinical practice favouring treatment of asymptomatic carotid patients with medical therapy alone

The ACST-1 showed clearly that, even among patients taking triple-drug therapy (i.e. statins, antithrombotic and antihypertensive medications), immediate carotid surgery halved the long-term risk of stroke\(^1\) (see Scientific summary, Figure a). Despite this finding, many commentators argued strongly that, because of improvements in medical therapy and a resulting reduction in the risk of carotid-related stroke, the risks of intervention were no longer justified. Although the use of antithrombotic and antihypertensive therapies was high in ACST-1, statin use was uncommon at the start of the trial but increased to around 80% by the end of follow-up. Statin therapy has been proven to reduce ischaemic strokes and may be particularly effective against carotid-related events (e.g. the risk of CEA was halved by allocation to 40 mg of simvastatin in the Heart Protection Study).\(^12\) Accordingly, it is possible that better statin therapy (higher doses and longer duration) may have reduced the prevalence of ischaemic stroke observed in ACST-1. However, counterbalancing this, periprocedural risks seen in ACST-1 are higher than currently seen in large registries, and intention-to-treat analyses of ACST-1 also substantially underestimate the actual benefit of immediate carotid surgery in long-term stroke prevention (as many patients in the no-surgery arm went on to have surgery without having symptoms). Nevertheless, rates of carotid intervention for asymptomatic disease have fallen in several northern European countries, that contributed strongly to ACST-1 (e.g. Norway, Sweden, Finland, the Netherlands, UK), and this has undoubtedly impaired recruitment to ACST-2.
Concerns about the short-term safety of carotid stenting

In 2010, a study comparing carotid stenting with surgery in symptomatic patients [International Carotid Stenting Study (ICSS)] reported interim results, which showed a significantly higher stroke risk associated with stenting. Asymptomatic patients are different from symptomatic patients in whom atheromatous carotid stenosis has recently caused a stroke and, hence, are likely to be unstable and at a high risk of distal embolisation during stenting. Furthermore, some stenters in the ICSS were very inexperienced and there is a clear relationship between individual and centre CAS volume and clinical outcomes. But, despite the fact that the ICSS did not provide a fair comparison of stenting versus surgery and recruited a different patient population to ACST-2, many commentators and clinicians mistakenly applied the results of the ICSS to asymptomatic carotid patients and preferred CEA to stenting for those patients with asymptomatic carotid stenosis in whom intervention was considered necessary.

Meta-analysis plans

Over 5000 patients randomised to carotid endarterectomy versus carotid artery stenting can detect plausible differences in outcomes between carotid endarterectomy and carotid artery stenting, and ACST-2 will provide most of these patients

Individual surgical trials are frequently too small to answer important questions reliably, particularly when considering clinically relevant subgroups (e.g. women and the elderly), who are commonly under-represented in RCTs. In 2014, it became apparent that a target of 5000 ACST-2 participants was no longer realistic. But current and projected recruitment rates suggest that a total of 3600 patients by the end of 2019 is achievable.

The Carotid Stenosis Triallists’ Collaboration (CSTC) was formed to pool the results of individual carotid studies to allow individual patient data meta-analyses and hence provide uniquely reliable evidence to answer key questions facing clinicians who manage patients with carotid artery stenosis. Through the CSTC, ACST-2 investigators have secured agreement to pool individual patient data from ACST-2 and three other trials that directly compared CEA with CAS in asymptomatic patients – CREST-1 (1182 patients), SPACE-2 (Stent Protected Angioplasty in asymptomatic carotid artery stenosis versus endarterectomy) (320 patients randomised to CAS vs. CEA before three-way trial abandoned) and ACT-1 (NCT00106938: 1450 patients randomised 3 : 1 CAS vs. CEA, equivalent to two-thirds as many randomised 1 : 1) – thereby yielding the equivalent of about 2400 additional patients. If ACST-2 recruits 3600 patients and pools these data with the CREST-1, SPACE-2 and ACT-1 cohorts, the resulting total of 6000 should more than suffice to identify types of patient in whom one procedure is clearly better than the other, and to assess reliably any effects on disabling and fatal stroke.

Recruitment strategy developed to reach target of 3600 by end 2019

One-third of all carotid procedures performed in Europe are carried out in Italy, a further one-third are carried out in Germany and the remainder are carried out in the rest of Europe. Accordingly, a recruitment strategy was developed focusing on Italy, which was already the top recruiting country in ACST-2, and Germany, where participation in ACST-2 had been hampered by SPACE-2 (another carotid trial being run in Germany, Austria and Switzerland and which was perceived as competing with ACST-2).

To maximise recruitment in Italy, we sought to encourage established sites to recruit more patients and to set up new high-volume sites. An ACST-2 recruitment co-ordinator was appointed who was fluent in Italian and English, had prior experience of working in carotid research and had access to a wide network of vascular surgeons and interventional radiologists across Italy. Working closely with the other ACST-2 office staff and the principal investigators, several new Italian sites were established and recruitment activity in existing Italian sites was maintained or enhanced. Trial profile-raising activities occurred at key Italian vascular meetings and communication between collaborators and trial staff was improved by a dedicated Italian collaborators’ newsletter (see Appendix 3).
In Germany, the closure of SPACE-2 facilitated ACST-2 expansion. SPACE-2 was originally designed as a three-way trial (CAS vs. CEA vs. medical therapy) but it failed to recruit. It was subsequently redesigned as two ‘two-arm trials’, directly comparing either CAS with medical therapy or CEA with medical therapy (a design subsequently employed by CREST-2). Unfortunately recruitment to this new design also failed, largely because participating hospitals received no payment for managing carotid patients medically, but substantial income for treating them with either surgery or stenting. Consequently, in 2015 the German funding agency withdrew support but has prudently provided funds to allow continued follow-up of all 513 randomised participants in both trial designs.\textsuperscript{15}

For some time ACST-2 had been in dialogue with several SPACE-2 investigators, who had sought to encourage SPACE-2 centres in Germany to consider randomising patients to ACST-2 when not suitable for the redesigned SPACE-2 (i.e. when intervention was considered necessary and hence enrolment in a trial with a medical therapy alone-arm inappropriate). However, it had proved difficult to successfully run both trials side by side. Hence, the closure of SPACE-2 enabled several high-volume German (and Austrian) sites to join ACST-2. Some of these sites, which have a strong track record of participating in randomised carotid trials, are now recruiting well and German recruitment rates are expected to rise over the next few years. These recruitment rates could conceivably approach those seen in Italy. We have German representation on our Trial Steering Committee and ACST-2 principal investigators attend German vascular surgical and interventional radiology meetings regularly, thereby raising the profile of ACST-2 in Germany, identifying new collaborators and encouraging recruitment nationally.

The ACST-2 has also sought to broaden its recruitment base by expanding into Brazil and China. Our experience in Brazil is limited to São Paolo (a large conurbation with a population of > 40 million and a recognised destination for complex health care in South America). The identification of potential centres in Brazil is co-ordinated by an academic vascular surgeon in a local university hospital. He has already recruited substantial numbers of patients to ACST-2 since joining in 2015 and several other high-volume sites are in the late stages of set-up. In contrast, our experience in China has been less positive despite long-standing collaborative links with several large academic hospitals throughout China, facilitated by the Fuwai–Oxford Research Collaboration, which has led to the inclusion of > 70,000 patients in CTSU trials. Four ACST-2 sites were established in Beijing and Shanghai with enthusiastic local collaborators but they failed to recruit significant numbers of patients. The barriers to recruitment in China were twofold: first, patients commonly had a strong preconception as to their preferred treatment, with most preferring carotid stenting and; second, carotid stents were much more expensive than surgery. Consequently, those who could afford to pay for a carotid stent were unwilling to be randomised to either surgery or stenting, with a 50% chance of being allocated to a procedure they perceived to be inferior. Moreover, those unable to afford the extra costs of a carotid stent could not be randomised in ACST-2, lest they be allocated to carotid stenting.

**Cost analysis**

**Streamlined trial design necessary to provide reliable evidence at reasonable cost**

High-quality RCTs are needed to guide clinical practice and there have been many examples of clinicians being misled by non-randomised studies or small RCTs, resulting in either under- or overtreatment and consequent patient harm. With good background therapies and declining event rates, modern trials need to be large scale and this fact, coupled with an increasing regulatory burden, may make appropriately sized studies unaffordable. However, if sufficient attention is paid at the outset to ensure a streamlined trial design, such studies can be delivered at a reasonable cost. Examples of streamlining in ACST studies include a brief trial protocol, broad inclusion criteria based entirely on the ‘uncertainty principle’, simplified clinical record forms at randomisation and follow-up (i.e. limited to a single side of A4, unless a periprocedural stroke or death has occurred, in which case a further single-sided form is required). As a consequence, ACST studies are relatively inexpensive, costing one-tenth of the equivalent era US trials and with 50% more patients (Table 6).
Large trials commonly need to recruit internationally, particularly when rates of intervention using procedures under investigation in the UK are low. Some may argue that if a procedure is not commonly performed in the UK then it should not be the subject of a UK-funded trial. However, the UK is recognised as being a slow adopter of innovation in health care, partly owing to constrained health-care resources and also to the centralised control on NHS budgets. Such innate conservatism may have some advantages but it is both unreasonable and possibly harmful to delay the rigorous evaluation of new technologies until they become widely used in the UK.

Around 80% of ACST-2 participants are from countries outside the UK and, hence, some overseas expenditure is inevitable. In ACST-2, this spending is limited to a modest £100 per-patient payment to local collaborators on receipt of the 1-month post-procedure follow-up and, more recently, a contribution to the salary of a part-time recruitment co-ordinator for Italy. However, the overwhelming majority of funding is spent in the UK on staff costs and overheads to support the ACST-2 office.

Trials such as ACST-1 and ACST-2 not only need to be large but also need to last long enough to determine the long-term durability of the procedures being assessed to prevent stroke. ACST-1 reported results at 5 and 10 years and is currently acquiring data to assess the lifetime effects of carotid surgery in asymptomatic patients. The ACST-2 will report 4-year follow-up results in 2020, but much more informative results may only emerge in 2025, when 10-year follow-up data are available, which will provide uniquely reliable evidence about the long-term durability of carotid surgery versus CAS for the prevention of stroke. No responsible funding agency can commit large sums of money for ≥10 years at the outset of a study. However, particularly in trials of preventative surgery for which the early years of follow-up are inevitably dominated by periprocedural hazards, prolonged follow-up must be an absolute requirement. When the trial has been carefully and correctly carried out, funding after the trial interventions should follow. Recruitment without retention and follow-up is a pointless and disincentivising exercise, a waste of research resources and arguably unethical.

Using a careful trial design, long-term follow-up of trial participants after intervention can be achieved at a low cost. In ACST-1 and ACST-2, clinicians report 1-month outcomes (periprocedural stroke, MI and death), thereafter, annual follow-up (for stroke and death) is achieved by means of an annual questionnaire (usually mailed directly to the participant). For ACST-2, this has proven to be a robust and acceptable method of follow-up, with a 95% response rate for the most recent questionnaire (in 2015). In ACST-1, data on incident stroke and cause-specific mortality are currently being sought from routine health records held by the Health and Social Care Information Centre (now known as NHS Digital) thereby enabling effectively life-long follow-up at minimal expense.
Chapter 9  Conclusion

Carotid artery stenosis causes around 20,000 strokes in the UK each year. Many patients have no prior symptoms or have failed to recognise warning signs, and about half die or are severely disabled by their first stroke. Our ACST-1 trial showed that, even on good triple therapy (including statins), stroke risk for the next 10 years could be halved by preventative surgery (CEA). Two recent carotid trials are now including asymptomatic patients (ECST-2, current recruitment 180/2000 planned, and CREST-2, current recruitment 300/2840 planned) comparing a stenting or surgery procedure with no procedure. Should these confirm the ACST-1 finding of additional benefit from a procedure in certain patients then, throughout the 2020s and beyond, the key question will be which procedure to recommend. With new technology and increasing experience, CAS can now rival or prove superior to CEA. The ACST-2 is the only trial now recruiting that directly compares CEA with stenting and will provide uniquely reliable evidence about the short-term safety and, perhaps more importantly, the long-term durability of surgery compared with stenting in patients with asymptomatic carotid stenosis. There will be an initial report in 2020, describing 4-year follow-up for 3600 patients randomised to CEA versus CAS, and a subsequent report in 2025 with around 10-year follow-up. Until then, how to intervene on asymptomatic patients with a carotid stenosis will be based on patient and professional preferences alone.
Acknowledgements

First and foremost, the principal acknowledgement is to the patients taking part in the trial, now and in the future. Second, to the funders to date (HTA programme and BUPA Foundation), to the UK Stroke Association, to all the UK and international collaborators, our office staff, the Steering and Data Monitoring Committees as well as to the trial Endpoint Review and Technical Management Committees. We also acknowledge the support of the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme. Finally, to the CTSU and Epidemiological Studies Unit, the Nuffield Department of Population Health, University of Oxford, Oxford, UK, and the Nuffield Department of Surgery, University of Oxford, Oxford, UK, for their invaluable support.

Alison Halliday and Richard Bulbulia, together with Richard Peto, Hongchao Pan (Statistical Co-principal Investigators) and Leo Bonati (Neurological Co-principal Investigator) are responsible for the design, conduct and analysis of ACST-2.

Contributions of authors

Richard Bulbulia (Co-principal Investigator and Consultant Vascular Surgeon) and Alison Halliday (Chief Investigator and Professor of Vascular Surgery) coauthored this report.

Publications


Data sharing statement

The ACST-2 data will be held in accordance with the Nuffield Department of Population Health Data Access and Sharing Policy. We have agreed to pool ACST-2 data with other similar trials under the auspices of the CSTC.
References


REFERENCES


Appendix 1  Trial flow diagram

ACST-2 trial design

Patient with asymptomatic stenosis is identified and duplex Doppler confirms tight stenosis

The ACST-2 trial is discussed during the patient's clinic appointment and a patient information leaflet is given out to allow the patient to fully consider entry into the trial

MRI/CTA shows that both CEA and CAS are anatomically practicable

Informed consent is obtained from the patient and documented via completion of a written consent form

Randomisation

Patient will be on appropriate medical therapy

CEA  CAS

Follow-up by patient visit at 1 month post intervention

Annual follow-up by post from ACST-2 for 5–10 years

Stroke/MI/death

Economic evaluation
Appendix 2  Hub-and-spoke model for ACST-2 in North East England
Appendix 3  Italian collaborators’ newsletter

ACST-2 a SICVE 2016

Save the date! Quest’anno ACST-2 vi invita ad un breve incontro per i collaboratori al National SICVE Meeting, dove i nostri collaboratori potranno condividere le loro esperienze con due dei investigatori principali di ACST-2: il Prof. Richard Bulbulia e Prof.ssa Alison Halliday.

ACST-2 Collaborator’s meeting, Belgrade 2016

Un ringraziamento caloroso a tutti i collaboratori che hanno generosamente dedicato del tempo per il nostro Collaborator’s Meeting, quest’anno a Belgrado, Serbia. L’esperienza e conoscenza italiana della malattia dell’arteria carotide si sono sempre apprezzate dal pubblico internazionale.

Il gruppo italiano ha avuto un’opportunità per conoscere meglio, e condividere un’esperienza unica in una città interessante, come Belgrado.

Grazie ancora ai nostri presentatori: Nicola Tusini (Reggio Emilia), Gianluca Faggioni (Bologna), e Sonia Ronchey (Roma).

C.A.P.V.T Mundi – Roma

Prof.ssa Halliday è stata contenta di incontrare tanti collaboratori in occasione della conferenza C.A.P.V.T Mundi a Roma a maggio di quest’anno, dove ha presentato “Le nuove intuizioni nel processo ACST-2” durante la sessione dedicata alle carotide.

Nuovi Centri Italiani

Siamo lieti di annunciare tre nuovi centri italiani per lo studio ACST-2:
• Azienda Ospedaliero-Universitaria di Ferrara - Dott. Francesco Mascoli e Dott.ssa Elpiniki Tsolaki,
• Ospedale Villa Scassi, Genova - Prof. Gianantonio Simonini e Prof. Paolo Rubartelli
• Istituto G. Giglio di Cefalù - Dott.ssa Alessia Giaquinta.

Benvenuti!!

Gli articoli dei collaboratori:

Chiediamo a tutti i nostri Collaboratori italiani di scrivere un articolo per il notiziario per condividere le vostre idee e raccontarci le vostre esperienze con ACST-2. Trovate qui sotto i nostri primi articoli:


Dott. Renato Casana, Responsabile Servizio di Chirurgia Vascolare dell’Istituto Auxologico Italiano IRCCS con il suo Team ha superato il sorprendente risultato di 200 pazienti arruolati con il titolo di “Overall Top Recruitment Center.” Ci racconta perché ha scelto di aderire al trial, “Attualmente non abbiamo dei dati certi offerti da un trial multicentrico a lungo termine su di una ampia popolazione di pazienti asintomatichi che ci dica effettivamente quale sia la tecnica più idonea per il trattamento della stenosi carotide, [e] dopo aver preso visione di tutta la documentazione del trial, ho trovato che lo studio fosse stato progettato e strutturato in maniera estremamente accurata ma al contempo era di facile gestione.” Ci racconta anche come sono riusciti ad arruolare un numero così elevato di pazienti.

“Credo di poter dire che la chiave del successo si basa su tre principi fondamentali:
1. Collaborazione a 360° gradi tra tutti componenti del Team oltre che interdisciplinare/interdipartimentale e con i Medici di Medicina Generale che sono poi coloro che indirizzano il Paziente al Centro.
2. Sovrapponibili competenze degli Operatori tra procedura di CAS e CEA
3. Perseveranza nell’arruolamento ed entusiasmo per lo studio.”
Euro Cup Challenge
L'Italia è attualmente al primo posto assieme alla Germania ed all’Austria per la Euro Cup Challenge. I finali saranno tenuti il 9 luglio, quindi dateci un’occhiata per l’Italia!

Arruolamento per Italia
Complimenti all’Italia. Ad oggi siamo a 22 pazienti per i tre mesi di aprile, maggio e giugno e a 51 pazienti arruolati per 2016

<table>
<thead>
<tr>
<th>Istituto Auxologico Italiano, Milano</th>
<th>19</th>
<th>Umberto I - ASO Mauriziano, Torino</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ospedale di Santa Maria, Reggio Emilia</td>
<td>10</td>
<td>NOCSAE, Modena</td>
<td>1</td>
</tr>
<tr>
<td>Policlinico di Bari, Bari</td>
<td>5</td>
<td>S.G. Moscati, Avellino</td>
<td>1</td>
</tr>
<tr>
<td>Policlinico Vittorio Emanuele, Catania</td>
<td>3</td>
<td>Ospedale di Perugia, Perugia</td>
<td>1</td>
</tr>
<tr>
<td>Ospedale di Circolo, Varese</td>
<td>3</td>
<td>Ospedale Sant Orsola, Bologna</td>
<td>1</td>
</tr>
<tr>
<td>A.C.O. San Filippo Neri, Roma</td>
<td>3</td>
<td>IRCCS Policlinico San Donato, Milano</td>
<td>1</td>
</tr>
<tr>
<td>Università la Sapienza, Roma</td>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Foto ACST-2 Collaborator’s meeting, Belgrade 2016
Appendix 4  Randomisation

ACST-2 RANDOMISATION FORM: complete top half (PART 1), then phone randomisation service & provide the information in Part 1

Which country are you in?

ACST-2 code for your hospital (if unknown, give hospital name, city & country and your code will be provided)

Name of randomising doctor (PRINT)

Family name(s) of patient (PRINT)

Main given name(s) of patient (PRINT)

d d m m y y Date of birth (day/month/year)

Sex (M=male, F=female)

Consent signed? (ie, consent form already signed, with contact details on it)

Y = YES, N = NO. MUST be YES

Angiogram OK? (ie, anatomically suitable by CTA, MRA or other angiogram both for CEA and for CAS)

Y = YES, N = NO. MUST be YES

Side? (Laterality of artery for randomisation, L = Left, R = Right)

Doppler % stenosis? (% stenosis on this side, by duplex doppler)

Echoluent? (Plaque >25% echoluent, Y/N or X = not known)

Contra-lateral stenosis? (% , by duplex doppler)

AF? (Known atrial fibrillation, Y/N)

Diabetic? (On drug or insulin therapy for diabetes, Y/N)

Systolic? (Systolic blood pressure, mmHg)

Diastolic? (Diastolic blood pressure, mmHg)

At the end of the phone call write down _____ – _____ – _____ 6-digit patient ID number (from phone service) and procedure allocated by randomisation _____ (CEA or CAS)

Plan for the allocated procedure (CEA/CAS) to be done soon

PART 2: Clinical data (not asked by telephone; can be completed a little later)

Left  Right  Data on both left and right carotid territories

Infarct on CT scan in the carotid territory?  Y/N/X  \( X = \) not done

Infarct on MRI scan in the carotid territory?  Y/N/X

Ever symptomatic in the carotid territory?  0 = never, 1 = A, fugax only, 2 = TIA, 3 = stroke

Other clinical data

CAD? (Definite history of coronary artery disease, Y/N)

Renal impairment?  (Y/N)

On anti-platelet therapy?  (Y/N)

On anti-coagulant therapy?  (Y/N)

On anti-hypertensive therapy?  (Y/N)

On lipid-lowering therapy?  (Y/N)

Total cholesterol  (mmol/L, to one decimal place [eg, 5.0] or mg/dL, [eg, 200]; X = not available)

HDL cholesterol

When completed, please keep copy in hospital notes and fax/post original to

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Bulbulia et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Appendix 5  One-month form

ACST-2 1-MONTH POST-PROCEDURE FORM: complete about 1 month after CEA/CAS

Name & address of doctor (or other person) completing this form (PRINT)

ACST 6-digit patient ID (eg 41-02-34) from randomisation or consent form, or PRINT patient’s main names:

d d / m m / y y

Date of birth (day/month/year)

Which procedure (CEA/CAS) was first attempted on the randomised artery? Give details below

Either: (1) CEA; Or: (2) CAS; Then: (1 or 2) procedural details

Date of CEA

AND Name of Surgeon, Hospital & City (PRINT)

Side of intervention? (L = Left, R = Right)

Patch used? Y = YES, N = NO

Or: (2) Date of CAS

AND Name of Interventionalist, Hospital & City (PRINT)

Side of intervention? (L = Left, R = Right)

Type of stent? (S = Straight, T = Tapered)

Name of stent (PRINT)

Speciality of interventionalist? (S = Surgeon, R = Radiologist, C = Cardiologist, O = Other)

Cerebral protection device(s)? (N = None used, 1 = Distal balloon, 2 = Proximal occlusion, 3 = Filter)

Name(s) of CP device(s) (PRINT)

Then: (1 or 2) Procedural details (of CEA or of CAS)

Type of anaesthetic? (L = Local, G = General)

Anti-platelet drugs used? (A = Aspirin, C = Clopidogrel, O = Other, N = None); can enter 1 or 2 drugs

Hospital stay, to nearest whole day (99 = not yet discharged)

B. Post-procedure status

Date of post-procedure duplex Doppler

% stenosis by this duplex Doppler

(Ipsilateral cranial nerve damage from procedure? Y/N if YES, which cranial nerves? (eg, XII)

Left side

Right side

(& any comment, if stenosis remains)

Comment:

C. Other procedures done since randomisation

Any other procedures to this artery since randomised treatment? (CEA/CAS/N = None)

If YES give date

Any procedures to contralateral artery since randomisation? (CEA/CAS/N = None)

If YES give date

D. Events within 30 days after trial procedure (please answer ALL 3 questions)

D1 MI(s)? Y/N If YES, give date and give details on next page

D2 Stroke(s)? Y/N If YES, give date and give details on next page

D3 Death? Y/N If YES, give date and give details on next page

E. Current status (leave blank if dead) Date patient last seen

Systolic/diastolic blood pressure (mmHg)

Patient in hospital/nursing care now? Y/N (If YES, please PRINT address)

Currently on the following therapy? (Please answer ALL 6 questions Y/N)

Aspirin

Clopidogrel

Other anti-platelet

Anti-coagulant

Anti-hypertensive

Lipid-lowering

When completed, please keep copy in hospital notes and fax/post original(s) to
## ACST-2 1-MONTH POST-PROCEDURE FORM: page 2 (leave page 2 completely blank unless a narrative is needed or there is a stroke, MI or death on page 1)

ACST-2 6-digit patient ID (eg 41-02-34) from randomisation or consent form, or PRINT patient’s main names: ____________________________

If there was any peri- or post-procedural stroke, MI or death (within 1 month), describe briefly how the procedure went, its outcome and the clinical course and current status (with any relevant comments)

### Details of major events within 1 month of the trial procedure (page 1, part D)

<table>
<thead>
<tr>
<th>Time of event(s) after procedure (hours/days: please specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any comments on how the event(s) seemed to relate to the procedure?</td>
</tr>
</tbody>
</table>

### D1 Myocardial infarction within 1 month

- Clinical symptoms? Y/N
- Definite ST-segment changes? Y/N
- Definite enzyme changes? Y/N
- Hospitalised for this event? Y/N

If YES, length of stay (days, to the nearest whole day: 99 = not yet discharged)

### Any comments (eg, on any additional infarcts)?

#### D2 Stroke within 1 month (If more than one, comment on all below)

- Laterality? (L = Left & R = Right carotid territory, O = Other; specify: ____________________________)
- Type? (I = Ischaemic, H = Haemorrhagic, U = Unknown)
- Stroke confirmed by CT/MRI? Y/N (If YES, please send copy of report to ACST-2 office)
- Status from stroke at present (modified Rankin scale 0-6; see below)
- Hospitalised (or institutionalised) for this event? Y/N

If YES, length of stay (days, to the nearest whole day: 99 = not yet discharged)

### D3 Death within 1 month

<table>
<thead>
<tr>
<th>Cause(s) of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any comments?</td>
</tr>
</tbody>
</table>

### Any additional comments or information (as narrative)?

(eg, why allocated procedure not done; how procedure went; any further MIs or strokes; timing, location, nature & severity of all strokes etc.):  

### Modified Rankin Scale (NB If patient has stroke then dies of unrelated cause, describe stroke anyway)

0. No symptoms at all from the stroke.
1. No significant disability despite some symptoms: able to carry out usual duties and activities.
2. Slight disability from the stroke: unable to carry out all previous activities but able to look after own affairs without assistance.
3. Moderate disability from the stroke: requiring some help, but able to walk without assistance.
4. Moderately severe disability from the stroke: unable to walk without assistance and unable to attend to own bodily needs without assistance.
5. Severe disability from it: bedridden, incontinent and requiring constant nursing care and attention.
6. Died directly or indirectly from the stroke.
Appendix 6  One-year form

International study of stroke prevention procedures
(Annual questionnaire; please complete BOTH pages)

Today's date:  

Patient name (please PRINT)  

Address (please PRINT), if different from that on the letter  

Patient ID:  

(incl. tel & email, if known)  

(from letter, to avoid mix-ups)  

Please tick a box to say who filled out this form  

[ ] Patient  

[ ] Carer  

[ ] Friend/relative  

[ ] Other  

We hope you have been well since leaving hospital after the neck artery procedure (CEA/CAS) you had when you first joined the study, but if not then please tell us.

1. Since you were last contacted  

[ ] Yes, or  

[ ] No.  

If YES, what was the approximate date?  

[ ] dd/mm/yyyy  

Which side of your body was affected?  

[ ] Left  

[ ] Right  

[ ] Neither side  

[ ] Both sides  

[ ] Don't know  

Where were you treated? (can tick more than 1)  

[ ] Home  

[ ] Hospital/Clinic  

[ ] Other (eg, nursing home)  

In total, how long were you in a hospital, clinic or nursing home because of it?  

[ ] days, or  

[ ] weeks, or  

[ ] months, or  

[ ] tick if still there  

Do you know the name and address of a doctor who saw you (or of the hospital you went to)?  

Name (PRINT):  

Address (PRINT):  

2. If you have had a stroke, how are you now? (Tick ONE box)  

[ ] No symptoms from the stroke  

[ ] Minor problems, but I can carry out everything I usually do  

[ ] A few problems from the stroke, but I can manage without help  

[ ] Problems from the stroke, I now need help with things  

[ ] Because of the stroke I now need help with most things  

[ ] Anything else you’d like to tell us?  

3. Since your first CEA/CAS, have you had any further neck artery procedures?  

Tick box if YES:  

[ ] Operation (CEA) on my LEFT neck artery  

[ ] Date / (month/year, approx)  

[ ] Stent (CAS) in my LEFT neck artery  

[ ] Date / (month/year, approx)  

[ ] Operation (CEA) on my RIGHT neck artery  

[ ] Date / (month/year, approx)  

[ ] Stent (CAS) in my RIGHT neck artery  

[ ] Date / (month/year, approx)  

If any answer is YES, did you have a stroke within the first month after the procedure? Yes or No  

[ ]  

4. Which medications do you take regularly?  

Please PRINT the NAMES and DOSAGES of all prescription medicines you take regularly (i.e., on most days), or state NOT KNOWN  

continued over the page...
# International study of stroke prevention procedures
(Annual questionnaire; please complete BOTH pages)

## 5. Contact details

You gave us this information when you joined this study. We may need to contact one of these people if we cannot contact you when we write to you again next year.

<table>
<thead>
<tr>
<th>Your family doctor</th>
<th>Your first friend or relative (1)</th>
<th>Your second friend or relative (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please give new contact details, if they differ from those above (thereby renewing your permission for us to contact them if necessary)

<table>
<thead>
<tr>
<th>New name or contact details* for my family doctor (PRINT)</th>
<th>New name or contact details* for my first friend or relative (PRINT)</th>
<th>New name or contact details* for my second friend or relative (PRINT)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* (including tel. & email, if known)

Thank you very much. Do you have any comments, further information or questions?

<table>
<thead>
<tr>
<th>Name of person completing this form, signature and date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Patient ID: [ ] [ ] [ ]

Please put this form in the prepaid envelope provided (no stamp is needed),

OR post it in another envelope (with a stamp) to [ ] [ ] [ ] [ ] [ ] [ ]
This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.